Glasgow-based biopharmaceutical company Mironid has raised £34 million in a Series B funding round, with the Scottish National Investment Bank joining the syndicate through an £8.4 million equity investment.
The round, announced on 5 August 2026, will support clinical development of Mironid’s small molecule therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD), described in the announcement as “a life-threatening hereditary kidney disease.”
The Scottish National Investment Bank joins existing investors Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde.
Mironid was founded through collaboration involving the University of Strathclyde and Heriot-Watt University. Under CEO Neil Wilkie, the company has progressed a series of drug development programmes that target specific enzymes to generate novel and differentiated therapies for a range of diseases with high unmet medical need.
ADPKD is described in the announcement as “one of the more prevalent rare diseases and the most common hereditary kidney disorder” — but one with limited treatment options. It is characterised by uncontrolled growth of fluid-filled cysts on the kidney.
Mironid’s first-in-class small molecule LoAc drug candidates are designed to directly target the abnormally high kidney cAMP levels that drive cyst formation.
Mironid CEO Neil Wilkie said: “ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60.
“Securing funding from such a high-caliber syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD. This financing will allow us to progress the clinical development of our lead candidate, bringing us closer to transforming the treatment landscape for patients with rare kidney diseases.”
Paul Callaghan, Director of Innovation at the Scottish National Investment Bank, said: “Our investment in Mironid reflects our commitment to backing impactful Scottish businesses with high-growth potential.
“Mironid exemplifies Scotland’s growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease.
“We are pleased to join a committed group of investors to support the company through this critical stage of development, helping it translate world-class research into clinical progress, commercial opportunity and potential patient benefit.”
An Important Life-Sciences Deal
The round is one of the more substantial Scottish life-sciences deals of the summer, combining a strategic investment from Scotland’s development bank with continued backing from a global syndicate — including Roche’s corporate venture arm and specialist European life-sciences funds Sofinnova Partners, Epidarex Capital and BioGeneration Ventures.
For the Scottish research ecosystem, Mironid is a live example of a Scottish biopharma company founded through collaboration with the University of Strathclyde and Heriot-Watt University.
